[ad_1]
BBC – Coronavirus
posted on 4/2/2021 7:44 PM
The National Health Surveillance Agency (Anvisa) approved this Wednesday (03/31) the emergency use of the vaccine against covid-19 produced by the Belgian company Janssen, controlled by Johnson & Johnson.
The request for authorization for emergency use was made by the company to the Brazilian health agency on March 24.
According to the Ministry of Health, there are already 38 million doses of this vaccine contracted: 16.9 million should be available between July and September, and another 21.1 million between October and December 2021.
The vaccine has already been approved for emergency use in the United States, Canada, and European countries. There are also doses ordered by the World Health Organization’s (WHO) Covax Facility program, which seeks to collect and distribute vaccines more evenly around the world.
Due to its storage and application characteristics, the immunizer is considered an important weapon in the global fight against coronavirus. The company plans to make 1 billion doses of the Janssen COVID19 (Ad26.COV2-S) vaccine, the official name of the vaccine, this year.
Single dose: ‘the best option in pandemic scenarios’
Unlike other immunizers that are already in use around the world, this one can be stored in a common refrigerator, dispensing super cold storage, and is applied in a single 0.5 ml dose.
“The World Health Organization (WHO) considers a single-dose vaccine to be the best option in pandemic settings,” said Paul Stoffels, Johnson & Johnson’s chief scientific officer.
The data presented by the company show an effectiveness of 66.9% for mild and moderate cases, and 76.7% for severe cases, after 14 days of application.
In testing, there were no deaths or hospitalizations among the volunteers, indicating that the vaccine is safe.
The immunizer uses a common cold virus, manipulated in the laboratory to make it harmless. It then carries part of the genetic code of the coronavirus to the body, but safely. This is enough for the body to recognize the threat and then learn how to fight the coronavirus.
The process is similar to the approach used in the vaccine developed by the University of Oxford and the AstraZeneca company.
Five vaccines approved in Brazil
Emergency use is envisaged to accelerate the release of a COVID-19 treatment, provided that the responsible institution submits data from clinical trials (human trials) and continues to inform the health agency of new discoveries or serious adverse events. you must be notified within 24 hours.
With the decision on the Janssen immunizer, Brazil has accumulated five approved vaccines, according to Anvisa, including those from Pfizer-BioNTech; Oxford-AstraZeneca; CoronaVac and Covishield.
“With the approval of this vaccine, Brazil ranks among the countries in the world that have the highest number of approved vaccine protocols. This demonstrates the agency’s commitment to promoting and protecting the health of the population. This protection and promotion It means evaluating with the criteria, and considering the exceptionality that the moment demands, the processes that are submitted to Anvisa, ”Romison Rodrigues, one of the agency’s directors, said in a press release.
You already saw our new videos in Youtube? Subscribe to our channel!
